Latest Insider Transactions at Pfizer Inc (PFE)
This section provides a real-time view of insider transactions for Pfizer Inc (PFE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PFIZER INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PFIZER INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2022
|
Michael Mc Dermott Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,133
-4.97%
|
$398,517
$49.18 P/Share
|
|
Feb 26
2022
|
Michael Mc Dermott Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
12,340
+12.87%
|
$308,500
$25.6 P/Share
|
|
Feb 26
2022
|
William R Carapezzi Jr Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
14,514
-8.62%
|
$711,186
$49.18 P/Share
|
|
Feb 26
2022
|
William R Carapezzi Jr Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
21,193
+19.52%
|
$529,825
$25.6 P/Share
|
|
Feb 26
2022
|
Douglas M Lankler Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
57,431
-17.89%
|
$2,814,119
$49.18 P/Share
|
|
Feb 26
2022
|
Douglas M Lankler Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
77,709
+30.81%
|
$1,942,725
$25.6 P/Share
|
|
Feb 26
2022
|
Frank A Damelio Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
93,977
-7.49%
|
$4,604,873
$49.18 P/Share
|
|
Feb 26
2022
|
Frank A Damelio Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
127,160
+16.36%
|
$3,179,000
$25.6 P/Share
|
|
Feb 26
2022
|
Sally Susman Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
48,430
-15.05%
|
$2,373,070
$49.18 P/Share
|
|
Feb 26
2022
|
Sally Susman Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
63,580
+26.89%
|
$1,589,500
$25.6 P/Share
|
|
Feb 24
2022
|
Jennifer B. Damico SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,893
+14.99%
|
-
|
|
Feb 23
2022
|
William R Carapezzi Jr Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
16,744
-10.49%
|
$820,456
$49.07 P/Share
|
|
Feb 23
2022
|
William R Carapezzi Jr Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
25,632
+23.61%
|
$692,064
$27.34 P/Share
|
|
Feb 23
2022
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,509
-15.16%
|
$1,725,414
$46.87 P/Share
|
|
Feb 23
2022
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
8,154
-20.44%
|
$399,546
$49.07 P/Share
|
|
Feb 23
2022
|
Jennifer B. Damico SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
11,748
+35.16%
|
$317,196
$27.34 P/Share
|
|
Feb 23
2022
|
Frank A Damelio Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
114,219
-9.35%
|
$5,596,731
$49.07 P/Share
|
|
Feb 23
2022
|
Frank A Damelio Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
153,789
+19.45%
|
$4,152,303
$27.34 P/Share
|
|
Feb 23
2022
|
Angela Hwang President, Global Biopharma |
SELL
Payment of exercise price or tax liability
|
Direct |
14,682
-40.27%
|
$719,418
$49.07 P/Share
|
|
Feb 23
2022
|
Angela Hwang President, Global Biopharma |
BUY
Exercise of conversion of derivative security
|
Direct |
21,359
+50.0%
|
$576,693
$27.34 P/Share
|
|
Feb 23
2022
|
Rady A Johnson Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
24,421
-14.16%
|
$1,196,629
$49.07 P/Share
|
|
Feb 23
2022
|
Rady A Johnson Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
35,457
+27.97%
|
$957,339
$27.34 P/Share
|
|
Feb 23
2022
|
Douglas M Lankler Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
84,861
-26.19%
|
$4,158,189
$49.07 P/Share
|
|
Feb 23
2022
|
Douglas M Lankler Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
115,342
+38.84%
|
$3,114,234
$27.34 P/Share
|
|
Feb 23
2022
|
Michael Mc Dermott Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
10,328
-6.5%
|
$506,072
$49.07 P/Share
|
|
Feb 23
2022
|
Michael Mc Dermott Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
14,952
+15.5%
|
$403,704
$27.34 P/Share
|
|
Feb 23
2022
|
Payal Sahni Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,589
-17.5%
|
$469,861
$49.07 P/Share
|
|
Feb 23
2022
|
Payal Sahni Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
13,884
+32.08%
|
$374,868
$27.34 P/Share
|
|
Feb 23
2022
|
Sally Susman Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
57,170
-18.65%
|
$2,801,330
$49.07 P/Share
|
|
Feb 23
2022
|
Sally Susman Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
76,895
+31.6%
|
$2,076,165
$27.34 P/Share
|
|
Feb 23
2022
|
Mikael Dolsten President R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
29,767
-8.42%
|
$1,369,282
$46.87 P/Share
|
|
Jan 31
2022
|
Lidia Fonseca Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,680
-16.14%
|
$347,360
$52.69 P/Share
|
|
Dec 17
2021
|
Albert Bourla Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
123,055
+21.55%
|
$3,199,430
$26.47 P/Share
|
|
Dec 17
2021
|
Mikael Dolsten President R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
71,187
+16.84%
|
$2,135,610
$30.17 P/Share
|
|
Dec 03
2021
|
Rady A Johnson Executive Vice President |
SELL
Open market or private sale
|
Direct |
19,000
-2.6%
|
$1,007,000
$53.44 P/Share
|
|
Dec 02
2021
|
Alexander R Mackenzie Executive Vice President |
SELL
Open market or private sale
|
Direct |
41,360
-32.15%
|
$2,233,440
$54.26 P/Share
|
|
Nov 26
2021
|
Sally Susman Executive Vice President |
SELL
Open market or private sale
|
Direct |
44,308
-2.68%
|
$2,392,632
$54.52 P/Share
|
|
Nov 26
2021
|
Douglas M Lankler Executive Vice President |
SELL
Open market or private sale
|
Direct |
40,000
-3.82%
|
$2,160,000
$54.38 P/Share
|
|
Nov 12
2021
|
Angela Hwang President, Global Biopharma |
SELL
Open market or private sale
|
Direct |
26,170
-41.24%
|
$1,282,330
$49.61 P/Share
|
|
Nov 11
2021
|
Mikael Dolsten President R&D |
SELL
Open market or private sale
|
Direct |
59,664
-2.65%
|
$2,983,200
$50.31 P/Share
|
|
Nov 11
2021
|
Mikael Dolsten President R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
199,548
+19.84%
|
$4,988,700
$25.28 P/Share
|
|
Nov 11
2021
|
John D Young Group President |
SELL
Open market or private sale
|
Direct |
150,000
-3.43%
|
$7,500,000
$50.09 P/Share
|
|
Aug 31
2021
|
Aamir Malik Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
43,412
+49.79%
|
-
|
|
Aug 13
2021
|
Jennifer B. Damico SVP & Controller |
SELL
Open market or private sale
|
Direct |
1,661
-7.27%
|
$79,728
$48.3 P/Share
|
|
Jul 30
2021
|
Jennifer B. Damico SVP & Controller |
SELL
Open market or private sale
|
Direct |
2,500
-17.95%
|
$105,000
$42.86 P/Share
|
|
Jun 16
2021
|
Ronald E Blaylock Director |
BUY
Bona fide gift
|
Indirect |
4,750
+50.0%
|
-
|
|
Jun 16
2021
|
Ronald E Blaylock Director |
SELL
Bona fide gift
|
Direct |
4,750
-36.54%
|
-
|
|
May 07
2021
|
John D Young Group President |
SELL
Bona fide gift
|
Direct |
8,830
-1.88%
|
-
|
|
May 05
2021
|
Jennifer B. Damico SVP & Controller |
SELL
Open market or private sale
|
Direct |
2,500
-15.39%
|
$100,000
$40.82 P/Share
|
|
Feb 27
2021
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
43,855
-13.93%
|
$1,491,070
$34.07 P/Share
|